0
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
12/31/2022, 4:59 AM
Summary of Bill HR 4065
One key aspect of the bill is the establishment of a Chronic Kidney Disease Task Force, which will be responsible for developing a comprehensive strategy to improve the prevention, diagnosis, and treatment of CKD. The task force will also work to increase awareness of CKD among healthcare providers and the general public.
Additionally, the bill includes provisions to increase funding for research into CKD, with a focus on identifying risk factors, improving early detection methods, and developing new treatment options. The goal is to ultimately reduce the prevalence of CKD and improve outcomes for individuals living with the disease. Overall, Bill 117 HR 4065 represents a bipartisan effort to address the growing public health crisis of chronic kidney disease in the United States. By focusing on research and treatment improvements, the bill aims to make a meaningful impact on the lives of individuals affected by CKD.
Congressional Summary of HR 4065
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
This bill modifies provisions relating to Medicare coverage of treatments for chronic kidney disease.
Specifically, the bill expands the Medicare annual wellness visit to include chronic kidney disease screening and allows certain Medicare beneficiaries who have End Stage Renal Disease (ESRD) to enroll in Medicare supplemental policies. It also (1) provides for alternative payment methodologies for certain new drugs, biologics, and devices that are renal dialysis services; (2) revises quality measures; (3) establishes an incentive payment methodology; and (4) increases access to kidney disease education services.
The bill also extends the coordination period (from 30 months to 42 months) during which private health insurers may serve as the primary payers for Medicare beneficiaries with ESRD.
